A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: A validation of current staging systems and a new prognostic nomogram

Annals of Surgery

Volumn 259, Issue 2, 2014, Pages 204-212

  Ellison, Trevor A ^a   Wolfgang, Christopher L ^a   Shi, Chanjuan ^c   Cameron, John L ^a   Murakami, Peter ^d   Mun, Liew Jun ^a   Singhi, Aatur D ^a   Cornish, Toby C ^a   Olino, Kelly ^a   Meriden, Zina ^a   Choti, Michael ^a,b   Diaz, Luis A ^b   Pawlik, Timothy M ^a   Schulick, Richard D ^e   Hruban, Ralph H ^a,b   Edil, Barish H ^e  

^a Department of Surgery ^*  (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

AJCC; ENETS; grade; nomogram; nonfunctional; pancreatic neuroendocrine tumors; staging systems

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NOMOGRAM; OVERALL SURVIVAL; PANCREATIC NEUROENDOCRINE TUMOR; PERINEURAL INVASION; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

EID: 84892924219     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31828f3174     Document Type: Article

References (28)

1. Edge SB,ByrdDR. Exocrine and endocrine pancreas. In: AJCC Cancer Staging Manual. 7th ed. Philadelphia, PA: Springer; 2010:241-249.
2. Martin RCG, Kooby DA, Weber SM, et al. Analysis of 6,747 pancreatic neuroendocrine tumors for a proposed staging system. J Gastrointest Surg. 2011;15:175-183.
3. Niederle MB, Hackl M, Daserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909-918.
4. Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29:3044-3049.
5. Goh BKP, Chow PKH, Tan YM, et al. Validation of five contemporary prognostication systems for primary pancreatic endocrine neoplasms: results from a single institution experience with 61 surgically treated cases. ANZ J Surg. 2011;81:79-85.
6. Hurtuk MG, Godambe AS, Shoup M, et al. Support for a postresection prognostic score for pancreatic endocrine tumors. Am J Surg. 2011;201:406-410.
7. Oberstein PE, SaifMW. Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO AnnualMeeting." Chicago, IL, USA; June 3-7, 2011. JOP. 2011;12:358-361.
8. KulkeMH, Bendell J, Kvols L, et al. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011;4:29.
9. Scarpa A, Mantovani W, Capelli P, et al. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23:824-833.
10. Saif MW. Pancreatic neoplasm in 2011: an update. JOP. 2011;12:316-321.
11. Williams ED, Sandler M. The classification of carcinoid tumors. Lancet. 1963;1:238-239.
12. Kl̈oppel G. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2011;18:S1-S16.
13. Capella C, Heitz PU, Ḧofler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch. 1995;425: 547-560.
14. Klimstra DS,Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-712.
15. Sellner F, Thalhammer S, Stattner S, et al. TNM stage and grade in predicting the prognosis of operated, non-functioning neuroendocrine carcinoma of the pancreas: a single-institution experience. J Surg Oncol. 2011;104:17-21.
16. Rindi G. The ENETS guidelines: the new TNM classification system. Tumori. 2010;96:806-809.
17. Kl̈oppel G, Couvelard A, Perren A, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology. 2009;90:162-166.
18. Liszka L, Pajak J, Mrowiec S, et al. Discrepancies between two alternative staging systems (European Neuroendocrine Tumor Society 2006 andAmerican Joint Committee on Cancer/Union for International Cancer Control 2010) of neuroendocrine neoplasms of the pancreas. A study of 50 cases. Pathol Res Pract. 2011;207:220-224.
19. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. http://www.R-project.org/.
20. Therneau T. A package for survival analysis in S. R package version 2.37-4. http://CRAN.R-project.org/package=survival. Accessed April 12, 2013.
21. Harrell FE. Design package. R package version 2.3-0. http://cran. rproject. org/src/contrib/Archive/Design. Accessed April 12, 2013.
22. Dong X, Li Y, Hess KR, et al. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. Oncologist. 2011;16:61-70.
23. Yi M, Mittendorf EA, Cormier JN, et al. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011;29:4654-4661.
24. Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview of the value of Ki-67 immunostaining. Endocr Pathol. 2008;19:282-288.
25. Altman DG, Vergouwe Y, Royston P, et al. Prognosis and prognostic research: validating a prognostic model. BMJ. 2009;338:b605.
26. Strosberg JR, CheemaA,Weber JM, et al. Relapse-free survival in patientswith nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256:321-325.
27. Oberstein PE, Saif MW. Update on novel therapies for pancreatic neuroendocrine tumors. JOP. 2012;13:372-375.
28. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011;331:1199-1203.